Role of the EGFR‑KDD mutation as a possible mechanism of acquired resistance of non‑small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report

He,Cheng; Wang,Yong

doi:10.3892/mco.2021.2463

Role of the EGFR‑KDD mutation as a possible mechanism of acquired resistance of non‑small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report

Authors:
- Cheng He
- Yong Wang
View Affiliations

Affiliations: Department of Thoracic Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui 230000, P.R. China, Department of Medical Oncology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230000, P.R. China
Published online on: December 10, 2021 https://doi.org/10.3892/mco.2021.2463
Article Number: 30
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) are currently considered as the standard therapy for patients with advanced non‑small cell lung cancer (NSCLC) who have EGFR‑activating mutations. However, despite an initially profound response to these drugs, these patients ultimately develop drug resistance. The most common resistance mechanism is the development of a secondary mutation in EGFR (T790M), although activation of the MNNG/HOS transforming gene (MET), amplification of the Erb‑B2 receptor tyrosine kinase 2 gene and histological transformation to small cell lung cancer may also lead to resistance. In addition, there may be additional, rare mechanisms leading to resistance that remain unidentified. Mutations in the EGFR kinase domain duplication (EGFR‑KDD) are rare, although they act as oncogenic drivers in NSCLC. To the best of our knowledge, all studies to date have reported EGFR‑KDD as the primary mutation in NSCLC. The aim of the present study was to report the case of an EGFR‑KDD mutation in a patient with NSCLC who developed acquired resistance to gefitinib, but responded well to afatinib. Therefore, EGFR‑KDD mutation is an additional potential mechanism underlying the development of acquired resistance to EGFR‑TKIs.

View Figures

View References

1	Lim ZF and Ma PC: Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 12(134)2019.PubMed/NCBI View Article : Google Scholar
2	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar
3	Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, et al: First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): A double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 13:1161–1170. 2012.PubMed/NCBI View Article : Google Scholar
4	Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.PubMed/NCBI View Article : Google Scholar
5	Ko B, Paucar D and Halmos B: EGFR T790M: Revealing the secrets of a gatekeeper. Lung Cancer (Auckl). 8:147–159. 2017.PubMed/NCBI View Article : Google Scholar
6	Normanno N, Maiello MR, Chicchinelli N, Iannaccone A, Esposito C, De Cecio R, D'alessio A and De Luca A: Targeting the EGFR T790M mutation in non-small-cell lung cancer. Expert Opin Ther Targets. 21:159–165. 2017.PubMed/NCBI View Article : Google Scholar
7	Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, et al: EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov. 5:1155–1163. 2015.PubMed/NCBI View Article : Google Scholar
8	Lababede O and Meziane MA: The eighth edition of TNM staging of lung cancer: Reference chart and diagrams. Oncologist. 23:844–848. 2018.PubMed/NCBI View Article : Google Scholar
9	Nie H, Zhou X, Shuzhang D, Nie C, Zhang X and Huang J: Palbociclib overcomes afatinib resistance in non-small cell lung cancer. Biomed Pharmacother. 109:1750–1757. 2019.PubMed/NCBI View Article : Google Scholar
10	Du Z, Gallant JN, Sheehan J, Meiler J and Lovly CM: Intramolecular dimerization of EGFR kinase domain duplication as a novel activation mechanism. J Thoracic Oncol. 12 (Suppl)(S1536)2017.
11	Baik CS, Wu D, Smith C, Martins RG and Pritchard CC: Durable response to tyrosine kinase inhibitor therapy in a lung cancer patient harboring epidermal growth factor receptor tandem kinase domain duplication. J Thoracic Oncol. 10:e97–e99. 2015.PubMed/NCBI View Article : Google Scholar
12	Zhu YC, Wang WX, Xu CW, Tan QH, Li JY, Zhuang W, Song ZB, Du KQ, Chen G, Lv TF and Song Y: Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib. J Thorac Dis. 10:E359–E363. 2018.PubMed/NCBI View Article : Google Scholar
13	Wang J, Li X, Xue X, Ou Q, Wu X, Liang Y, Wang X, You M, Shao YW, Zhang Z and Zhang S: Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC. Int J Cancer. 144:2677–2682. 2019.PubMed/NCBI View Article : Google Scholar
14	Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M and Adamo V: Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario. Int J Mol Sci. 20(1431)2019.PubMed/NCBI View Article : Google Scholar
15	Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul S, Arcila ME, et al: The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin Cancer Res. 26:5701–5708. 2020.PubMed/NCBI View Article : Google Scholar
16	Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L: Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29 (Suppl 1):i10–i19. 2018.PubMed/NCBI View Article : Google Scholar
17	Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, et al: Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC. J Thorac Oncol. 13:1248–1268. 2018.PubMed/NCBI View Article : Google Scholar
18	Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162. 2014.PubMed/NCBI View Article : Google Scholar